Cara B http://kamagrafrance.eu/nutrition/ . Ebbeling, Ph.D., Henry A. Feldman, Ph.D., Virginia R. Chomitz, Ph.D., Tracy A. Antonelli, M.P.H., Steven L. Gortmaker, Ph.D., Stavroula K. Osganian, M.D., Sc.D., and David S. Ludwig, M.D., Ph.D.: A Randomized Trial of Sugar-Sweetened Beverages and Adolescent BODYWEIGHT The intake of sugar-sweetened drinks among adolescents1 has increased in tandem with the prevalence of pediatric obesity in the United States,2 suggesting a causal relationship. At the moment, a substantial proportion of high-school students consume sugar-sweetened beverages, including carbonated soda, sports drinks, energy drinks, and sweetened coffees and teas highly.3 Sugar-sweetened beverages are the leading source of added sugars in the dietary plan of a wide range of racial and ethnic groups.4 According to nationally representative data, obese and overweight adolescents obtain more than 300 kcal each day from these products, amounting to an average of 15 percent of their total daily energy intake.5 Short-term feeding studies also show greater energy intake and pounds gain with the consumption of sugar-sweetened beverages than with drinks containing artificial sweeteners,6 and prospective observational studies show positive associations with the risk of obesity and related complications.7 However, the findings from the few randomized relatively, controlled trials made to examine the consequences of sugar-sweetened drinks on body weight have got not been conclusive,8-10 and the use of public wellness measures to reduce the intake of sugar-sweetened drinks remains controversial.11,12 We previously conducted a 6-month pilot research10 involving normal-weight, overweight, and obese adolescents who habitually consumed sugar-sweetened beverages.
Ralf Gold, M.D., Ludwig Kappos, M.D., Douglas L. Arnold, M.D., Amit Bar-Or, M.D., Gavin Giovannoni, M.D., Krzysztof Selmaj, M.D., Carlo Tornatore, M.D., Marianne T. Sweetser, M.D., Ph.D., Minhua Yang, M.S., Sarah I. Sheikh, M.D., and Katherine T. Dawson, M.D. For the DEFINE Study Investigators: Placebo-Controlled Phase 3 Research of Oral BG-12 for Relapsing Multiple Sclerosis Oral BG-12 has been investigated for the treatment of multiple sclerosis. Swelling and oxidative stress are central pathologic factors in multiple sclerosis.1,2 Immune cell activation and infiltration into the central nervous system are thought to result in widespread cellular damage, potentially due to the dysregulated creation and launch of reactive oxygen and nitrogen species, such as hydrogen peroxynitrite and peroxide, and proinflammatory stimuli.3 This mix of toxic factors ultimately effects in demyelination and neurodegeneration, causing disease activity and progression of disability.1,4 BG-12 may also play a role in modulating immune-cell responses by shifting dendritic-cell differentiation,5 suppressing proinflammatory-cytokine creation, or inhibiting proinflammatory pathways directly.